Freshworks Inc vs uniQure N.V. Ordinary Shares — how do they compare? Freshworks Inc trades at $13.69 (market cap $3.57B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: Freshworks Inc is far larger — about 2.5× uniQure N.V. Ordinary Shares's market cap, and Freshworks Inc is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 40 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| FRSH | QURE | |
|---|---|---|
Market Cap | $3.57B | $1.45B |
Volume | 4,701,335 | 3,323,243 |
Sector | Technology | Health |
52-Week High | $13.92 | $70.59 |
52-Week Low | $6.88 | $9.03 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $2.94B | $707.46M |
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.90, down 0.14% with a bullish technical outlook. The company achieved its first GAAP profitability in Q2 2026, beating earnings expectations with $0.17 EPS versus $0.13 expected. Revenue growth remains strong at 16% YoY, with improving margins and positive cash flow trends. Analyst consensus is evenly split between Buy and Hold ratings with a $14.60 price target.
FRSH presents a compelling growth story with accelerating profitability and AI-driven product expansion. Key risks include competitive pressures in the SaaS sector and execution challenges in enterprise market penetration. The stock's current valuation at 22x P/E appears reasonable given the company's growth trajectory and improving financial metrics.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →